{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027672","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-08-13T20:10:53+00:00","discovered_at":"2026-08-13T20:12:10.238677+00:00","generated_at":"2026-08-13T20:12:15.591008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Eton Q2 revenue $37.6M (+99% YoY), raises FY26 guidance to >$145M","bullets":["Q2 net revenue $37.6M vs $18.9M YoY; GAAP EPS $0.35, non-GAAP $0.43.","Adjusted EBITDA $16.2M (43% margin) vs $3.1M (16%) YoY; EBITDA $14.1M.","FY26 revenue guidance raised to >$145M (from >$120M); Adjusted EBITDA margin ≥35% (from ≥30%).","HEMANGEOL relaunch May 1; ~95% patient conversion by end of June; ASN-001 licensed.","Acquired U.S. rights to IMPAVIDO (launch Sept 2026); KHINDIVI PAS submitted for expanded indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027672","json":"https://secwatch.observer/filing/0001437749-26-027672.json","markdown":"https://secwatch.observer/filing/0001437749-26-027672.md","text":"https://secwatch.observer/filing/0001437749-26-027672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/0001437749-26-027672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/eton20260608_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:12:15.591008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}